Skip to main content
Year archive

RELIEF Therapeutics Holding AG — 2021 filings

All 70 regulatory filings released by RELIEF Therapeutics Holding AG (RLF) in 2021, sourced directly from the official regulator.

70 Filings
2021 Period
2021 filings (70)
Filing Released Lang
Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
Regulatory Filings
2021-12-30 English
Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
Regulatory Filings
2021-12-28 English
Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Regulatory Filings
2021-12-16 English
Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
Regulatory Filings
2021-12-15 English
Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
Legal Proceedings Report
2021-12-10 English
Relief Therapeutics Announces Executive Changes
Board/Management Information
2021-11-30 English
Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
Regulatory Filings
2021-11-29 English
Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
Regulatory Filings
2021-11-24 English
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
Legal Proceedings Report
2021-11-24 English
Relief Therapeutics Launches Level 1 ADR Program in the United States
Regulatory Filings
2021-11-18 English
Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information
Legal Proceedings Report
2021-11-12 English
Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100(TM) (Aviptadil)
Regulatory Filings
2021-11-11 English
Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development
Board/Management Information
2021-11-09 English
Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA
Regulatory Filings
2021-11-05 English
Relief Therapeutics Takes First Step to Create an ADR Program in the United States by filing a Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
Capital/Financing Update
2021-11-03 English
Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
Legal Proceedings Report
2021-11-03 English
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients
Earnings Release Q4 2021
2021-10-27 English
Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation
Regulatory Filings
2021-10-26 English
Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn(R) AOS for Hard-to-Heal Ulcers
Regulatory Filings
2021-10-20 English
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
Regulatory Filings
2021-10-15 English
Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)
Regulatory Filings
2021-10-13 English
Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation
Regulatory Filings
2021-10-07 English
Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100(TM) (Aviptadil)
Legal Proceedings Report
2021-10-07 English
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders
Regulatory Filings
2021-10-06 English
Relief's Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating Nexodyn(R) AOS Highly Effective Treatment to Support Healing of Hard-to-Heal Leg Ulcers
Regulatory Filings
2021-09-30 English
Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil)
Legal Proceedings Report
2021-09-28 English
Relief Reports Half-Year 2021 Results and Provides Corporate Update
Report Publication Announcement H1 2021
2021-09-24 English
Relief's Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in Peer Reviewed Journal, Nutrients, Indicating Additional Potential Benefits of Its Physiomimic(TM) Technology
Earnings Release FY 2021
2021-09-21 English
Relief Therapeutics Provides Update on Regulatory Interactions in the United Kingdom and European Union Relating to Lead Drug Candidate, RLF-100 (Aviptadil)
Legal Proceedings Report
2021-09-13 English
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE(R) KRUNCH in Germany and Italy
Regulatory Filings
2021-09-09 English
Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Regulatory Filings
2021-09-08 English
Relief Therapeutics Comments on Certain Statements Made by NRx Pharmaceuticals in its Registration Statement on Form S-1 Filed on September 3, 2021
Legal Proceedings Report
2021-09-07 English
Relief Reports Regulatory Clearance in Germany to Commence a Multicenter, Double-blind, Randomized Phase 2 Clinical Trial to Evaluate Inhaled Aviptadil for the Treatment of Sarcoidosis
Legal Proceedings Report
2021-09-02 English
Relief Reports that U.S. Collaboration Partner has Announced a New Finding from Aviptadil Phase 2b/3 Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
Regulatory Filings
2021-08-31 English
Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19
Regulatory Filings
2021-08-19 English
RELIEF THERAPEUTICS Holdings AG: Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
Regulatory Filings
2021-08-09 English
Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia
Regulatory Filings
2021-07-28 English
Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita
M&A Activity
2021-07-28 English
Relief Therapeutics gibt eine Privatplatzierung in Hohe von CHF 15 Mio. bekannt
Share Issue/Capital Change
2021-07-26 German
Relief Therapeutics Announces CHF 15 Million Private Placement
Share Issue/Capital Change
2021-07-26 English
Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil
Regulatory Filings
2021-07-23 English
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting
Share Issue/Capital Change
2021-07-22 English
Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19
Environmental & Social Information
2021-07-20 English
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial
Legal Proceedings Report
2021-07-13 English
Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR
M&A Activity
2021-06-29 English
Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority
AGM Information
2021-06-21 English
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
Regulatory Filings
2021-06-16 English
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
Legal Proceedings Report
2021-06-02 English
Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer
Board/Management Information
2021-05-28 English
Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG
AGM Information
2021-05-27 English
Relief's Partner Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
Regulatory Filings
2021-05-25 English
Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders
Regulatory Filings
2021-05-18 English
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
Regulatory Filings
2021-05-17 English
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR
M&A Activity
2021-05-04 English
Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome
Regulatory Filings
2021-04-22 English
Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.
Legal Proceedings Report
2021-04-19 English
Relief Reports 2020 Financial Results and Provides Business Update
Earnings Release FY 2020
2021-04-15 English
Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant
Board/Management Information
2021-04-07 English
Relief Confirms Release of 60-Day Findings from Phase 2b/3 Clinical Trial of Intravenous RLF-100(TM) (aviptadil)
Legal Proceedings Report
2021-03-30 English
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of UCDs and MSUD
Regulatory Filings
2021-03-22 English
Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals
Regulatory Filings
2021-03-15 English
Relief gibt Privatplatzierung in der Hohe von CHF 10 Mio, bekannt
Share Issue/Capital Change
2021-03-12 German
Relief Announces CHF 10 Million Private Placement
Share Issue/Capital Change
2021-03-12 English
Relief Increases Issued Share Capital with Creation of Treasury Shares
Share Issue/Capital Change
2021-03-08 English
Relief Confirms Release of Preliminary Findings from Phase 2b/3 Trial of Intravenous RLF-100(TM) (aviptadil)
Regulatory Filings
2021-02-10 English
Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors
Board/Management Information
2021-02-09 English
Relief Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients
Regulatory Filings
2021-02-08 English
Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM
Share Issue/Capital Change
2021-01-21 English
Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil
M&A Activity
2021-01-20 English
Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM) (RLF-100(TM): aviptadil) in the I-SPY COVID-19 Trial
Regulatory Filings
2021-01-11 English